Affiliation:
1. Division of Clinical Microbiology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA
Abstract
Diagnostic testing for Lyme disease (LD) remains dependent on detection of antibodies to LD
Borrelia
using serologic assays, in adherence to the standard two-tiered testing (STTT) algorithm. We present the first analytic evaluation of the automated
Borrelia
B31 ViraChip IgM and IgG microarray immunoblot (MIB) assays (Viramed Biotech AG, Planegg, Germany) in comparison to two different, semiautomated blot assays for LD, including the
Borrelia
B31 ViraStripe IgM and IgG line immunoassays (LIAs) (Viramed) and the MarDx
Borrelia burgdorferi
IgM and IgG Western blot (WB) assays (Trinity Biotech, Carlsbad, CA), using prospectively collected sera (
n
= 411) and archived, clinically characterized samples (
n
= 91).
Publisher
American Society for Microbiology
Cited by
11 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献